Video

Organization Matches Survivors and Caregivers with 'Mentor Angels'

Author(s):

Jonny Imerman

A cancer diagnosis can happen so fast, it takes a lot to wrap one’s mind around it; however, Imerman Angels – a Chicago-based, global, peer-to-peer nonprofit support group – is here to help.

A cancer diagnosis can happen so fast, it takes a lot to wrap one’s mind around it; however, Imerman Angels — a Chicago-based, global, peer-to-peer nonprofit support group – is here to help.

As a result of his own experience with testicular cancer, founder Jonny Imerman connects patients, survivors and caregivers affected by cancer with mentors who have been through similar circumstances, providing support and encouragement for all stages of the cancer journey.

Imerman discussed the highly personalized process of partnering individuals seeking cancer support with a “mentor angel”— whether they are a patient, survivor or caregiver — so that no one has to face their cancer journey alone.

Related Videos
Image of man with black hair.
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Related Content
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Dr. Eric K. Singhi currently serves as an assistant professor in both the Department of General Oncology and the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, Texas.
January 27th 2025

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

Ryan Scott
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.